Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations

OPA1 mutations are the major cause of dominant optic atrophy (DOA) and the syndromic form DOA plus, pathologies for which there is no established cure. We used a ‘drug repurposing’ approach to identify FDA-approved molecules able to rescue the mitochondrial dysfunctions induced by OPA1 mutations. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Aleo, Serena J, Del Dotto, Valentina, Fogazza, Mario, Maresca, Alessandra, Lodi, Tiziana, Goffrini, Paola, Ghelli, Anna, Rugolo, Michela, Carelli, Valerio, Baruffini, Enrico, Zanna, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
General Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823107/
https://www.ncbi.nlm.nih.gov/pubmed/33231680
http://dx.doi.org/10.1093/hmg/ddaa244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823107/
https://www.ncbi.nlm.nih.gov/pubmed/33231680
http://dx.doi.org/10.1093/hmg/ddaa244

Ejemplares similares